Jesse Nussbaum
Overview
Explore the profile of Jesse Nussbaum including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
8
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Robbins J, Sands S, Maganti L, Crumley T, Fox-Bosetti S, Hussain A, et al.
J Clin Sleep Med
. 2024 Jul;
20(12):1905-1913.
PMID: 39069967
Study Objectives: Obstructive sleep apnea (OSA) is a highly prevalent disorder with serious health consequences but limited therapeutic options. For a subset of those with OSA, a key underlying mechanism...
2.
Nussbaum J, Cao X, Railkar R, Sachs J, Spellman D, Luk J, et al.
Vaccine
. 2023 Sep;
41(44):6488-6501.
PMID: 37777449
Human respiratory syncytial virus (RSV) causes a substantial proportion of respiratory tract infections worldwide. Although RSV reinfections occur throughout life, older adults, particularly those with underlying comorbidities, are at risk...
3.
Walford G, Bautmans A, Cannon C, Duncan K, Deschamps K, Matthews R, et al.
Clin Pharmacol Ther
. 2023 Jun;
114(3):569-577.
PMID: 37309988
Cell and gene therapy (CGT) describes a broad category of medicinal products with potential applications to prevent and treat human disease in multiple therapeutic areas. These therapies leverage the use...
4.
Chawla A, Largajolli A, Hussain A, Kleijn H, Ait-Oudhia S, Anton J, et al.
CPT Pharmacometrics Syst Pharmacol
. 2023 May;
12(8):1107-1118.
PMID: 37147897
Gefapixant, a P2X3-receptor antagonist, demonstrated objective and subjective efficacy in individuals with refractory or unexplained chronic cough. We report a population pharmacokinetic (PopPK) analysis that characterizes gefapixant pharmacokinetics (PKs), quantifies...
5.
Nussbaum J, Hussain A, Ford A, Butera P, Kitt M, Smith S, et al.
Lung
. 2022 Jun;
200(3):315-323.
PMID: 35670873
Purpose: Patients with chronic cough are typically female and have a mean age of ~ 60 years. However, initial pharmacokinetic (PK) characterization of the P2X3-receptor antagonist gefapixant, developed to treat...